Overview
- Government tallies show more than 10,351 infections and 5,026 deaths in the Democratic Republic of Congo, a figure reported on Saturday that places the Bundibugyo outbreak near a 50% reported fatality rate.
- The epidemic remains concentrated in eastern DRC provinces such as Ituri and North Kivu while linked cases have been detected in Kenya, Nigeria, Uganda and France, raising concerns about international spread.
- About 80% of new cases are occurring outside monitored contact chains and roughly one third of recorded deaths happen before patients reach treatment centers, leaving many infections undetected and untreated.
- Response operations are hampered by armed attacks on health workers and facilities, unpaid staff strikes that have shut treatment sites, and shortages of fuel and supplies that limit testing and patient transport.
- There is no licensed vaccine or approved antiviral for Bundibugyo; experimental trials are under way with a Phase II/III study that began enrolling in the DRC on October 23 and separate Oxford Phase I dosing in Uganda and Britain, underscoring that large-scale protection is not yet available.